Lapatinib Tablets, 250 mg, has been announced by pharma giant LUPIN after its alliance with Natco Pharma which received final approval for its ANDA from the United States Food and Drug Administration (US FDA).
The Lapatinib Tablets, 250 mg, are the generic equivalent of Tykerb Tablets, 250 mg, of Novartis Pharmaceutical Corporation.
The combination are indicated with Capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors over express human epidermal growth factor receptor 2 (HER2), and who have received prior therapy including an anthracycline, a taxane and trastuzumab. Letrozole for the treatment of postmenopausal women with hormone-receptor-positive metastatic breast cancer that over expresses the HER2 receptor, for whom hormonal therapy is indicated
